
01 / 04
Genuine Medicines
Tracked Shipping
Plain Packaging
Order Metadata
ReferenceGH·BIOMAB50
AvailabilityIn stock
SourceIndia
Delivery5–10 business days to your country
GH·BIOMAB50Anti-Cancer / Oncology Medicines
Biomab 50 mg Inj
Nimotuzumab is a prescription targeted cancer medicine used mainly to treat advanced squamous cell cancers of the head and neck, along with radiation or chemotherapy. In some countries it is also used for brain tumors (glioma), esophageal cancer, and pancreatic cancer. It is a monoclonal antibody that blocks the EGFR protein on cancer cells, which they need in order to grow and divide. It is given as an infusion into a vein by trained healthcare staff, and only under the supervision of a cancer specialist.
Order This Product
Send us a message on WhatsApp with this product name — we'll come back with the price and delivery options for your country.
Description
Nimotuzumab is a humanized monoclonal antibody that attaches to the epidermal growth factor receptor (EGFR) on the surface of cancer cells, blocking growth signals and making the cells more sensitive to radiation and chemotherapy. It is approved in several countries, including India, Cuba, and parts of Asia and Latin America, but not by the US FDA or EMA, so availability varies. It is prescribed for locally advanced head and neck cancer together with radiotherapy or chemoradiotherapy, for diffuse intrinsic pontine glioma and other high-grade gliomas in children and adults, and, depending on the country, for esophageal and pancreatic cancer. A common schedule is 200 mg given weekly as an intravenous infusion over about 30 to 60 minutes, often for six to eight weeks, followed by a maintenance schedule if advised, and the exact regimen is set by the oncologist. Antihistamines or other premedication may be given before the infusion, and patients are watched during and after it. Compared with other EGFR antibodies such as cetuximab, it is reported to cause milder skin rash and less severe diarrhea and low magnesium, which is one reason it is used in some settings. Common side effects include fever, chills, headache, nausea, vomiting, tiredness, mild skin rash, and mouth sores from the combined radiation or chemotherapy. Infusion reactions, with breathlessness, wheezing, facial swelling, or low blood pressure, are possible and need emergency care. Rarely, it can cause lung inflammation, so new cough or breathlessness must be reported at once, and blood tests for blood counts, salts, and kidney function are done during treatment. Fever or signs of infection during treatment need urgent medical attention. It should not be used in people with a known serious allergy to the medicine or its ingredients. It can harm an unborn baby, so effective contraception is advised during treatment and for several months afterward, and breastfeeding should be avoided. The doctor should know about all medicines being taken, and treatment should never be missed, changed, or stopped without the oncology team’s advice.
Specifications
- Composition
- Nimotuzumab
- Strength
- 50 mg
- Treatment
- Cancer Medicine
- Packaging Type
- Vial
- Packaging Size
- 1 Vial
How this product reaches you
- 1Global Healthcare sources this product from a manufacturer in India. The manufacturer name and country are part of the order record.
- 2It is shipped from India to your address. Carrier and delivery options depend on your country and order size.
- 3Your country's import rules apply — we help you understand them on chat.
